ELAVL1 and COVID-19: In addition, we find that niclosamide effectively inhibit HuR nucleo-cytoplasmic translocation, CD147 protein levels, and the increase of CD147 upon SARS-CoV-2 infection, thus, establishing a proof-of-principle to repurposing niclosamide as a functional CD147 inhibitor, as well as a drug for COVID-19.